Company / Revenue
TEVA PHARMACEUTICAL INDUSTRIES LTD Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$17.3B
FY2025
5-year range
$14.9B / $17.3B
FY2021-FY2025
Trend
+4.3%
vs FY2024
Sector context
#10 of 155
Health Care
What the data says
Among 155 Health Care companies, TEVA PHARMACEUTICAL INDUSTRIES LTD is in the top 6% for revenue. Revenue has increased for 3 consecutive years, from $14.9B in FY2022 to $17.3B in FY2025.
Based on SEC 10-K filings.
$17.3B in FY2025 with a 5-year CAGR of +0.7%. Top quartile in the Health Care sector.
Improved from $15.8B to $17.3B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +5.0%
- 5-Year CAGR
- +0.7%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 155This company $17.3B Sector average $4.5B
▼
+286.0% above sector average
Key checks
Key Insights
- TEVA PHARMACEUTICAL INDUSTRIES LTD's revenue has grown for 3 consecutive years.
- 5-year CAGR of +0.7%, indicating consistent growth.
- In FY2025, revenue increased 4.3% year-over-year.
- Ranks #10 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $17.3B | +4.3% |
| FY2024 | $16.5B | +4.4% |
| FY2023 | $15.8B | +6.2% |
| FY2022 | $14.9B | -6.0% |
| FY2021 | $15.9B | -4.7% |
| FY2020 | $16.7B | -1.4% |
| FY2019 | $16.9B | -7.6% |
| FY2018 | $18.3B | -16.4% |
| FY2017 | $21.9B | -0.2% |
| FY2016 | $21.9B | +11.5% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026